Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group

Lung Cancer

Volumn 18, Issue 1, 1997, Pages 57-70

  Buccheri, Gianfranco ^a,b,c   Ferrigno, Domenico ^a  

^a 'A Carle' Hosp of Chest Diseases   (Italy)

^b Ospedale A Carle ^*  (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Combination chemotherapy; MACC chemotherapy; MVP chemotherapy; Non small cell lung cancer; Platinum based chemotherapy, Phase III study

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; METHOTREXATE; MITOMYCIN C; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOMUSTINE; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; MITOMYCIN; QUALITY OF LIFE; VINDESINE;

EID: 0030741047     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00045-7     Document Type: Article

References (43)

1. Buccheri G. Chemotherapy and survival in non-small cell lung cancer: Three years later. Chest 1994;106:990-2.
2. Aisner I, Hansen HH. Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1981;65:979-86.
3. Buccheri G, Ferrigno D, Vola F, Curcio A. Combination of chemotherapy with methrotexate, adriamycin, cyclophosphamide, and CCNU (MACC) for non-small cell lung cancer: 4-year experience with 92 patients. Oncology 1989;46:212-6.
4. Buccheri G, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer after two or three cycles of MACC. Cancer 1989;63:428-32.
5. Buccheri G, Ferrigno D, Rosso A, Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990;6:87-98.
6. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei III E. Effects of lonidamine on the cytotoxycity of four alkylating agents in vitro. Cancer Chemother Pharmacol 1989;25:32-6.
7. Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu S, Frei III E. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 1991;51:780-4.
8. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res 1986;6:1245-50.
9. Buccheri G, Ferrigno D, Rosso A. A Phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer 1993;72:1564-72.
10. Buccheri G, Ferrigno D. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Eur J Cancer [A] 1994;30A:1424-31.
11. Alberti W, Anderson G, Bartolucci A, et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
12. Buccheri G. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress?. Lung Cancer 1994;11:115-7.
13. Ferrigno D, Buccheri G. Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer. Acta Oncol 1996;35:435-9.
14. World Health Organization. International histological classification of tumours. Berlin: Springer-Verlag, 1991.
15. Zubrod CG, Scheiderman MA, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;11:7-33.
16. Chahinian AP, Arnold DJ, Cohen JM, et al. Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. J Am Med Assoc 1977;237:2392-6.
17. Chahinian AP, Mandel EM, Holland JF, et al. MACC (methotrexate, adriamycin, cyclophosphamide, and CCNU) in advanced lung cancer. Cancer 1979;43:1590-7.
18. Mason BA, Catalano RB. Mytomicin, vinblastine and cisplatinum chemotherapy in non small-cell lung cancer. Proc Am Soc Clin Oncol (abstract) 1980;21:477 (Abstract).
19. Ruckdeschel J, Finkelstein DM, Ettinger DS, Mason BA, Creech RH. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, Generation V-A randomized comparison of four cisplatin containing regimens. J Clin Oncol 1985;3:72-9.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment: Cancer 1981;47:207-14.
21. Buccheri G, Vola F, Ferrigno D. Aspects of quality of life in patients with lung cancer: a three observer evaluation study. Int J Oncol 1993;2:537-44.
22. Longo LD, Duffley PL, DeVita VT, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-51.
23. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-9.
24. Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457-81.
25. Dixon WJ. BMDP: Statistical Software. Berkeley CA: University California Press, 1988:576-583.
26. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
27. Siegel S. Nonparametric Statistics for the Behavioural Sciences. New York: MacGraw-Hill, 1956.
28. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949:199-205.
29. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer 1993;10:21-33.
30. Johnson DH. Combined-modality therapy for unresectable, stage III non-small-cell lung cancer - Caveat emptor or caveat venditor. J Natl Cancer Inst 1996;88:1175-7.
31. Ogino H, Hayashi S, Kawasaki M, Nakanishi M, Hara N. Association of thrombosis-inducing activity (TIA) with fatal hypercoagulable complications in patients with lung cancer. Chest 1994;105:1683-6.
32. Ihde DC. Drug therapy: Chemotherapy of lung cancer. New Engl J Med 1992;327:1434-41.
33. Haraf DJ, Devine S, Ihde DC, Vokes EE. The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol 1992;19(Suppl 11):72-87.
34. Slevin ML, Staquet MJ. Randomized trials in cancer. A critical review by sites. In: Anonymous. Monograph Series of the European Organization for Research and Treatment of Cancer, vol. 15. New York: Raven Press, 1986:342-344.
35. Buccheri G, Ferrigno D, Curcio A, Vola F, Mattalia E. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer. Chemioterapia 1986;5:53-7.
36. Cormier Y, Bergeron D, La Forge J, et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982;50:845-9.
37. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med 1969;46:516-25.
38. Woods RL, Williams CJ, Levi J, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990;61:608-11.
39. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J, for the UCLA Solid Tumor Study Group. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989;63:1271-1278.
40. Kaasa S, Lund E, Thorud E, Hatlevoll R, Host H. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991;67:2443-7.
41. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991;9:1453-61.
42. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994;106(Suppl):320S-3S.
43. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agent followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:1602-13.